Teva Granted ANDA Approval for Eisai's Aciphex
This article was originally published in PharmAsia News
Executive Summary
Although Teva's ANDA for rabeprazole delayed-release tablets (Eisai's Aciphex) has been approved, the company told "The Pink Sheet" DAILY Feb. 22 that it will not immediately launch the product